Kirsch, Dylan E.
Tretyak, Valeria
Radpour, Sepeadeh
Weber, Wade A.
Nemeroff, Charles B.
Fromme, Kim
Strakowski, Stephen M.
Lippard, Elizabeth T. C.
Funding for this research was provided by:
Waggoner Center on Alcohol and Addiction Research, The University of Texas at Austin (Jones/Bruce Fellowship)
NIAAA (T32 AA07471, AA024933, R01 AA020637, K01 AA027573)
NIMH (MH117293)
National Institute on Alcohol Abuse and Alcoholism (R21 AA027884)
Article History
Received: 4 March 2020
Accepted: 21 December 2020
First Online: 8 January 2021
Competing interests
: We do not believe that any of these relationships could influence the reported results but we report them for transparency. SMS consults for Sunovian and Otsuka and holds research grants with Janssen. ETCL received funding for a Janssen-sponsored study through UT. In the last 3 years, CN has consulted to Xhale, Takeda, Taisho Pharmaceutical Inc., Signant, Sunovion Pharmaceuticals Inc., Janssen Research & Development, Magstim, Inc., Navitor Pharmaceuticals, Inc., Actify Neurotherapies, Intra-Cellular Therapies, Inc. CN is a Stockholder of Xhale, Celgene, Seattle Genetics, Abbvie, Antares, BI Gen Holdings, Inc., Corcept Therapeutics Pharmaceuticals Company, TC MSO, Inc., and Trends in Pharma Development, LLC. CN is a member of the scientific advisory boards of the Brain and Behavior Research Foundation (BBRF), Xhale, Anxiety Disorder Association of America (ADAA), Skyland Trail, Signant Health, Laureate Institute for Brain Research (LIBR), Inc. and on the board of directors of AFSP, Gratitude America, Chale Smart and ADAA. CN has had income sources or equity of 10,000 USD or more from American Psychiatric Publishing, Xhale, Signant Health, CME Outfitters, Actify Neurotherapies, Intra-Cellular Therapies, Inc., and Magstim. CN holds the following patents: method and devices for transdermal delivery of lithium (US 6375990B1), Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitter by ex vivo assay (US 7148027B2), and Compounds, Compositions, Methods of Synthesis, and Methods of Treatment (CRF Receptor Binding Ligand) (US 8551996 B2). All other authors declare no competing interests.